Source: Annual Congress 2013 –Pulmonary circulation: treatment
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Simonneau, A. M. D'Armini, H. A. Ghofrani, F. Grimminger, M. M. Hoeper, P. Jansa, N. H. Kim, C. Wang, M. R. Wilkins, A. Fritsch, N. Davie, G. Weimann, E. Mayer (Le Kremlin-Bicêtre, France; Pavia, Italy; Giessen, Hannover, Wuppertal, Bad Nauheim, Germany; Prague, Czech Republic; San Diego, United States Of America; Beijing, China; London, United Kingdom). An interim analysis of the phase III riociguat long-term extension study in CTEPH (CHEST-2). Eur Respir J 2013; 42: Suppl. 57, 1785

Member's Comments

No comment yet.

Related content which might interest you: Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST-1 study Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT-1 study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Measurement of gas transfer components using nitric oxide in post pulmonary endartectomy (PEA) chronic thromboembolic hypertension (CTEPH) patients Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Nitric oxide in acute testing in patients with pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 277s Year: 2004 Inhaled nitric oxide in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006 Ample safety margins exist for clinical development of inhaled AIR001 (Sodium nitrite) in pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Comparison of hemodynamic effects of inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with pulmonary hypertension (PH) Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Hemodynamic effects of different vasodilators in patients with type II pulmonary hypertension (PH) Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders Source: Eur Respir J 2002; 19: 664-671 Year: 2002 Exhaled nitric oxide levels in patients with pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Pathways in pulmonary arterial hypertension: the future is here Source: Eur Respir Rev 2012 21: 321-327 Year: 2012 Tolerance of long term nitric oxide treatment in severe arterial pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Infused nitric oxide in experimental pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 348s Year: 2007 The cycle of the nitric oxide metabolism in patients with COPD and chronic cerebrovascular diseases (CCVD) Source: Annual Congress 2013 –The vulnerable patient and ageing cells Year: 2013 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010